keyword
MENU ▼
Read by QxMD icon Read
search

Ivabradine

keyword
https://www.readbyqxmd.com/read/29332571/role-of-heart-rate-reduction-in-the-management-of-myocarditis
#1
Chen Guang-Yi, Ge Li-Sha, Li Yue-Chun
The morbidity of myocarditis demonstrates an upward tendency by years, is commonly defined as the inflammation of myocytes and is caused by multiple factors. With the development of the molecular biological technique, great breakthroughs in the diagnosis and understanding of pathophysiological mechanisms of myocarditis have recently been achieved. Several questions remain unresolved, however, including standard treatment approaches to myocarditis, which remain controversial and ambiguous. Heart rate, as an independent risk factor, has been shown to be related to cardiac disease...
January 10, 2018: Current Pharmaceutical Design
https://www.readbyqxmd.com/read/29330767/ivabradine-for-the-treatment-of-postural-orthostatic-tachycardia-syndrome-a-systematic-review
#2
REVIEW
Megan E Gee, Alicia K Watkins, Jamie N Brown, Emily J A Young
INTRODUCTION: Postural orthostatic tachycardia syndrome (POTS) impacts millions of patients, but there is currently no gold standard treatment for this condition. Ivabradine is a novel heart rate (HR) lowering agent that acts on the sinoatrial node cells by selectively inhibiting the If-current. OBJECTIVE: The objective of this systematic review is to evaluate the evidence for the efficacy and safety of ivabradine for the treatment of POTS. METHODS: MEDLINE (from 1956 to August 2017) and EMBASE (from 1957 to August 2017) were queried with the following search term: "postural orthostatic tachycardia syndrome" OR "postural tachycardia syndrome" OR "chronic orthostatic intolerance" AND "ivabradine...
January 12, 2018: American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions
https://www.readbyqxmd.com/read/29300199/recent-advances-in-heart-failure
#3
Mahwash Kassi, Bashar Hannawi, Barry Trachtenberg
PURPOSE OF REVIEW: Acute heart failure continues to be a challenge as there is limited benefit of numerous agents that have been tested. Cardiac resynchronization therapy remains standard of care, yet timing and need for implantable cardiac defibrillator has been brought into question with the recent randomized trials. Several recent advances have been made towards management of heart failure both in drug and device therapy. The purpose of this review is to provide an update on the most important recent studies on heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF)...
January 2, 2018: Current Opinion in Cardiology
https://www.readbyqxmd.com/read/29276898/-clinical-and-demographic-characteristics-of-an-outpatient-russian-population-with-chronic-heart-failure-at-the-time-of-enrollment-in-the-qualify-registry-for-evaluating-consistency-with-clinical-guidelines-on-drug-therapy
#4
S N Tereshchenko, I V Zhirov, A A Petrukhina
BACKGROUND: Chronic heart failure is the most common condition in patients with cardiovascular diseases. Therefore, evaluating consistency of doctor's recommendations with guidelines on drug therapy is a relevant issue. AIM: To evaluate consistency of doctor's recommendations with guidelines on drug therapy for CHF. MATERIALS AND METHODS: The study presents enrollment visit data for the Russian part of the international prospective registry, QUALIFY...
2017: Kardiologiia
https://www.readbyqxmd.com/read/29251762/drug-action-s-drug-marketing-and-clinical-medicine-suppression-of-ventricular-arrhythmogenicity-with-if-blockade-in-human-heart-failure-emerging-clinical-evidence-for-ivabradine-treatment-benefit-beyond-heart-rate-control
#5
https://www.readbyqxmd.com/read/29249470/heart-rate-as-a-prognostic-marker-and-therapeutic-target-in-acute-and-chronic-heart-failure
#6
Fabrizio Oliva, Paola Sormani, Rachele Contri, Carlo Campana, Valentina Carubelli, Antonio Cirò, Fabrizio Morandi, Giuseppe Di Tano, Andrea Mortara, Michele Senni, Marco Metra, Enrico Ammirati
Since increased heart rate (HR) is associated with higher mortality in several cardiac disorders, HR is considered not only a physiological indicator but also a prognostic and biological marker. In heart failure (HF), it represents a therapeutic target in chronic phase. The use or up-titration of beta-blockers, a milestone in HF with reduced left ventricular ejection fraction (LVEF) treatment, is at times limited by patients' hemodynamic profile or intolerance. Ivabradine, a HR-lowering drug inhibiting the f-current in pacemaker cells, has been shown to improve outcome in patients with chronic HF, in sinus rhythm with increased HR beyond beta-blocker therapy...
December 14, 2017: International Journal of Cardiology
https://www.readbyqxmd.com/read/29239349/influences-of-ivabradine-treatment-on-serum-levels-of-cardiac-biomarkers-sst2-gdf-15-supar-and-h-fabp-in-patients-with-chronic-heart-failure
#7
Peter Jirak, Dzeneta Fejzic, Vera Paar, Bernhard Wernly, Rudin Pistulli, Ilonka Rohm, Christian Jung, Uta C Hoppe, P Christian Schulze, Michael Lichtenauer, Atilla Yilmaz, Daniel Kretzschmar
Chronic heart failure (CHF) represents a major cause of hospitalization and death. Recent evidence shows that novel biomarkers such as soluble suppression of tumorigenicity (sST2), growth-differentiation factor-15 (GDF-15), soluble urokinase plasminogen activator receptor (suPAR) and heart-type fatty acid binding protein (H-FABP) are correlated with inflammatory and ischemic responses in CHF patients. In this study we examined the effects of Ivabradine that inhibited the hyperpolarization-activated cyclic nucleotide-gated channel (HCN channel, also called funny current If), thereby leading to selective heart rate reduction and improved myocardial oxygen supply on the cardiac biomarkers sST2, GDF-15, suPAR and H-FABP in 50 CHF patients at the University Hospital of Jena...
December 14, 2017: Acta Pharmacologica Sinica
https://www.readbyqxmd.com/read/29225577/if-channel-as-an-emerging-therapeutic-target-for-cardiovascular-diseases-a-review-of-current-evidence-and-controversies
#8
REVIEW
Hayelom G Mengesha, Tadesse B Tafesse, Mohammed H Bule
In 2015, non-communicable diseases accounted for 39.5 million (70%) of the total 56.4 million deaths that occurred globally, of which 17.7 million (45%) were due to cardiovascular diseases. An elevated heart rate is considered to be one of the independent predictors and markers of future cardiovascular diseases. A variety of experimental and epidemiological studies have found that atherosclerosis, heart failure, coronary artery disease, stroke, and arrhythmia are linked to elevated heart rate. Although there are established drugs to reduce the heart rate, these drugs have undesirable side effects...
2017: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/29196088/ivabradine-improves-left-ventricular-twist-and-untwist-during-chronic-hypertension
#9
Mathieu Jozwiak, Jonathan Melka, Mario Rienzo, Alain Bizé, Lucien Sambin, Luc Hittinger, Alain Berdeaux, Jin Bo Su, Belaid Bouhemad, Bijan Ghaleh
BACKGROUND: Left ventricular (LV) dysfunction develops during LV hypertrophy and particularly during tachycardia. Thus we investigated the effects of heart rate (HR) reduction with ivabradine, an If-channel blocker, on LV twist and untwist which represents myocardial deformation occurring during the overall systole and diastole and therefore provide valuable evaluation of global LV systolic and diastolic function. METHODS: Eight chronically instrumented pigs receiving continuous angiotensin II infusion during 28days to induce chronic hypertension and LV hypertrophy...
November 21, 2017: International Journal of Cardiology
https://www.readbyqxmd.com/read/29189314/ivabradine-for-treatment-of-refractory-tachycardia-in-a-patient-with-hypertrophic-cardiomyopathy
#10
Ahmed Subahi, Ahmed S Yassin, Hossam Abubakar, Joya Ganguly
No abstract text is available yet for this article.
November 7, 2017: American Journal of Therapeutics
https://www.readbyqxmd.com/read/29189171/inappropriate-sinus-tachycardia
#11
Mohammed Ruzieh, Abdelmoniem Moustafa, Ebrahim Sabbagh, Mohammad M. Karim, Saima Karim
Definition and diagnosis: Inappropriate Sinus Tachycardia (IST) is a clinical syndrome characterized by a sinus heart rate inexplicably higher than one hundred beats per minute at rest that is associated with symptoms like palpitations, dyspnea or dizziness in the absence of primary causes of tachycardia. The diagnosis requires exclusion of other causes of tachycardia including medications/substances (such as anti-cholinergic, beta-blocker withdrawal, caffeine, and alcohol) or medical conditions (such as panic attacks, pulmonary embolism, fever, hyperthyroidism, hypovolemia, anemia, and pain)...
November 29, 2017: Current Cardiology Reviews
https://www.readbyqxmd.com/read/29183646/a-risk-score-to-predict-the-absence-of-left-ventricular-reverse-remodeling-implications-for-the-timing-of-icd-implantation-in-primary-prevention
#12
Jordi Pérez-Rodon, Enrique Galve, Carmen Pérez-Bocanegra, Teresa Soriano-Sánchez, Jesús Recio-Iglesias, Eva Domingo-Baldrich, Mila Alzola-Guevara, Ignacio Ferreira-González, Josep Ramon Marsal, Aida Ribera-Solé, Laura Gutierrez García-Moreno, Luz María Cruz-Carlos, Nuria Rivas-Gandara, Ivo Roca-Luque, Jaume Francisco-Pascual, Artur Evangelista-Masip, Àngel Moya-Mitjans, David García-Dorado
BACKGROUND: A prophylactic implantable cardioverter defibrillator (ICD) in patients with heart failure and reduced left ventricular ejection fraction (HFrEF) is only indicated when left ventricular ejection fraction (LVEF) reassessment remains ≤35% after 3-6 months on optimal pharmacological therapy. However, LVEF may not improve during this period and the patient may be exposed to an unnecessary risk of sudden cardiac death. This study aimed to determine the incidence and predictors of the absence of left ventricular reverse remodeling (LVRR) after pharmacological treatment optimization in patients with HFrEF to design a risk score of absence of LVRR...
November 25, 2017: Journal of Cardiology
https://www.readbyqxmd.com/read/29161389/innovations-in-management-of-cardiac-disease-drugs-treatment-strategies-and-technology
#13
P Foëx
Within the last generation, the management of patients with heart disease has been transformed by advances in drug treatments, interventions and diagnostic technologies. The management of arterial hypertension saw beta-blockers demoted from first- to third-line treatment. Recent studies suggest that the goal of treatment may have to change to lower systolic blood pressures to prevent long-term organ damage. Today less than 15% of coronary revascularizations are surgical and more than 85% are done by interventional cardiologists inserting coronary stents...
December 1, 2017: British Journal of Anaesthesia
https://www.readbyqxmd.com/read/29157949/non-pci-cabg-therapies-for-refractory-angina
#14
REVIEW
Ki E Park, C Richard Conti
Angina persists for many patients despite modern medical therapy and/or revascularization, and this is referred to as refractory angina. All patients with refractory angina must be treated with aggressive risk factor modification plus optimized medical management. β-Blockers and nitrates are usually first-line agents; however most patients require multiple medications for refractory symptom control. Novel agents, such as ranolazine and ivabradine, as well as non-pharmacologic therapies, such as enhanced external counterpulsation and cardiac rehabilitation, may provide relief or reduction of angina...
October 20, 2017: Trends in Cardiovascular Medicine
https://www.readbyqxmd.com/read/29149941/pathophysiology-of-septic-shock
#15
REVIEW
James A Russell, Barret Rush, John Boyd
Fundamental features of septic shock are vasodilation, increased permeability, hypovolemia, and ventricular dysfunction. Vasodilation owing to increased nitric oxide and prostaglandins is treated with vasopressors (norepinephrine first). Increased permeability relates to several pathways (Slit/Robo4, vascular endothelial growth factor, angiopoietin 1 and 2/Tie2 pathway, sphingosine-1-phosphate, and heparin-binding protein), some of which are targets for therapies. Hypovolemia is common and crystalloid is recommended for fluid resuscitation...
January 2018: Critical Care Clinics
https://www.readbyqxmd.com/read/29146614/heart-rate-reduction-improves-biventricular-function-and-interactions-in-experimental-pulmonary-hypertension
#16
Olga Gomez, Kenichi Okumura, Osami Honjo, Mei Sun, Ryo Ishii, Bart Bijens, Mark K Friedberg
OBJECTIVES: To investigate mechanisms of heart rate (HR) reduction on biventricular function and interactions in experimental pulmonary arterial hypertension (PAH). METHODS: We compared cardiac-cycle mechanics and interventricular interactions in 15 sham, 8 monocrotaline-PAH, 9 PAH+carvedilol and 8 PAH+ivabradine rats. We used echocardiography to assess biventricular function, timing of cardiac- cycle events and septal position in PAH rats; and related HR reduction effect on biventricular function measured by echocardiography and conductance catheter...
November 16, 2017: American Journal of Physiology. Heart and Circulatory Physiology
https://www.readbyqxmd.com/read/29142810/the-role-of-ivabradine-in-diastolic-heart-failure-with-preserved-ejection-fraction-a-doppler-echocardiographic-study
#17
Federico Cacciapuoti, Valerio Massimo Magro, Michele Caturano, Diana Lama, Fulvio Cacciapuoti
Background: Ivabradine (IVA) is effective in patients with coronary artery disease (CAD) or systolic heart failure in sinus rhythm. Its action consists in reducing heart rate (HR) and improving the time of left ventricular (LV) diastolic filling. The aim of this study was to evaluate the effects of IVA added to conventional therapy on patients with diastolic heart failure (DHF) and preserved ejection fraction (HFpEF). Methods: We evaluated 25 patients with DHF in the New York Heart Association (NYHA) Class II-III and sinus rhythm...
October 2017: Journal of Cardiovascular Echography
https://www.readbyqxmd.com/read/29121737/ivabradine-well-tolerated-in-elderly-patients-with-systolic-heart-failure
#18
EDITORIAL
Christos Zivlas, Paul W X Foley
No abstract text is available yet for this article.
December 15, 2017: International Journal of Cardiology
https://www.readbyqxmd.com/read/29121732/quality-of-life-improvement-in-older-patients-with-heart-failure-initiated-on-ivabradine-results-from-the-uk-multi-centre-live-life-prospective-cohort-study
#19
D Zachariah, D Stevens, G Sidorowicz, C Spooner, N Rowell, J Taylor, R Kay, M S Salek, P R Kalra
AIMS: LIVE:LIFE is a multi-centre, open-label, prospective observational cohort study assessing health-related quality of life (HRQoL) in older patients with chronic heart failure (CHF) following initiation of ivabradine. The primary endpoint is change in Minnesota Living with Heart Failure Questionnaire (MLWHFQ) total score after 6months. METHODS AND RESULTS: Consenting patients aged ≥70years with CHF, in whom ivabradine was initiated within its licensed indication, were enrolled...
December 15, 2017: International Journal of Cardiology
https://www.readbyqxmd.com/read/29116618/treatment-of-stable-angina-with-a-new-fixed-dose-combination-of-ivabradine-and-metoprolol-effectiveness-and-tolerability-in-routine-clinical-practice
#20
Dimitar Divchev, Georg Stöckl
INTRODUCTION: In this prospective, multicenter, observational cohort study, the effectiveness and tolerability of the first fixed-dose combination (FDC) formulation of the selective heart rate reducing agent ivabradine and the beta-blocker metoprolol was evaluated in stable angina pectoris (AP) patients in a clinical practice setting. METHODS: Stable AP outpatients received a FDC of ivabradine and metoprolol (b.i.d.) for 4 months, in addition to cardiovascular standard therapy...
December 2017: Cardiology and Therapy
keyword
keyword
6588
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"